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Abstract 
Background: Diabetes mellitus (DM) is the commonest most common cause of end-stage 
renal disease (ESRD). ESRD is associated with increased morbidity and mortality. Our 
primary aim was to assess the impact of bariatric surgery on renal functionestimated 
glomerular filtration rate (eGFR) in patients with Type 2 DM (T2DM). Our secondary aim was 5 
to compare the impact of bariatric surgery vs. routine care on renal functioneGFR in patients 
with T2DM.   
Methods: A retrospective cohort analysis of adults with T2DM who underwent bariatric 
surgery at single center in the UK between January 2005 and December 2012. Renal 
function (measured by estimated glomerular filtration rate (eGFR))Data regarding eGFR was 10 
obtained from electronic patients records. eGFR was calculated using the MDRD 
(Modification of Diet in Renal Disease) formula. Data regarding patients with T2DM who did 
not undergo bariatric surgery (“routine care”) were obtained from patients attending the 
diabetes clinic at the same centre 2009-2011.  
Results: 163 patients were included (mean age 48.5±8.8 years, baseline Body Mass Index 15 
(BMI) (50.8±9.1kg/m2) and were followed for 3.0±2.3 years. Bariatric surgery resulted in an 
improvement in eGFR (median (IQR) 86.0 (73.0-100.0) vs. 92.0 (77.0-101.0) ml/min/1.73m2 
for baseline vs. follow-up respectively; p= 0.003) particularly in patients with baseline eGFR 
≤<60 ml/min/1.73m2 (48.0 (42.0-57.0) vs. 61.0 (55.0-63.0) ml/min/1.73m2; p= 0.004). After 
adjusting for baseline eGFR, glycated hemoglobin (A1C) (HbA1c), BMI, age and gender, 20 
bariatric surgery was associated with higher study-end eGFR compared to routine care 
(B=7.787, p=<0.001) 
Conclusion: Bariatric surgery results in significant improvements in renal functioneGFR in 
patients with T2DM, particularly in those with an eGFR ≤<60 ml/min/1.73m2, while routine 
care was associated with a decline in eGFR.  25 
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Introduction 
Chronic kidney disease (CKD) secondary to diabetes is the most common cause of end-stage 
renal disease (ESRD) and is associated with increased morbidity and mortality 1;2. About 20–30 
40% of patients with microalbuminuria can progress to overt proteinuria of which 20% will 
have progressed to ESRD within 20 years 1. CKD progression to ESRD requiring renal 
replacement therapy (RRT) is variable and depends on multiple modifiable and non-
modifiable factors such as obesity, blood pressure (BP), metabolic control, gender and 
ethnicity 3;4. 35 
Glycaemic and BP control and the use of renin–angiotensin–aldosterone system (RAAS) 
inhibitors are the mainstay of treatment in order to slow down the decline in renal function 
and the progression to ESRD; but despite better metabolic control in patients with Type 2 
diabetes mellitus (T2DM), ESRD remains very common 5. 
Obesity, which is very common in patients with T2DM, is also a modifiable risk factor in the 40 
development of CKD 6-8. The mechanisms linking obesity to CKD are complex and 
multifactorial including hypertension, activation of the sympathetic nervous system, 
activation of the RAAS, increased inflammation, low adiponectin, insulin resistance, 
obstructive sleep apnea (OSA) and endothelial dysfunction amongst others 8-11.  
Meta-regression analysis from 522 patients across 13 trials showed that independent of 45 
decline in mean arterial pressure, each 1 kg weight loss was associated with 110 mg (95% CI 
60-160 mg, p < 0.001) decrease in proteinuria and 1.1 mg (95% CI 0.5-2.4 mg, P = 0.011) 
decrease in microalbuminuria 12; potentially suggesting an important role for weight loss in 
the management of CKD and emphasizing the importance of obesity in the pathogenesis of 
CKD.  50 
3 
 
Bariatric surgery is the most effective treatment for obesity that results in sustained long 
term weight loss 13. Several randomized and non-randomized clinical trials showed that 
bariatric surgery was superior to intensive medical management in patients with T2DM 
particularly in regards metabolic parameters including hyperglycaemia, weight, BP, 
hypertriglyceridemia and low HDL 14-18. Diabetes remission rates following bariatric surgery 55 
were 30-90% depending on the definition of the remission used, length of follow up, the 
type of bariatric surgery and diabetes duration amongst other factors 14;16;17;19;20.  
Hence, due to its impact on multiple CKD and cardiovascular disease risk factors it would be 
expected that bariatric surgery could have a favourable impact on renal function in patients 
with T2DM. On the other hand, bariatric surgery might have no impact on renal function in 60 
the short-medium term due the effect of metabolic memory resulting in sustained vascular 
dysfunction despite improvements in metabolic control and weight loss 21. Bariatric surgery, 
particularly Roux-en-Y gastric bypass (RYGB), might even have a harmful effect on the 
kidneys due to possibility of chronic hyperoxaluria resulting in further insult to kidneys that 
are already damaged by diabetes22.   65 
The primary aim of this study was to assess the impact of bariatric surgery on renal function 
estimated glomerular filtration rate (eGFR) in patients with T2DM. A secondary aim was to 
compare the impact of bariatric surgery vs. routine care in patients with T2DM.  
Methods 
We conducted a retrospective cohort analysis of adult patients (≥ 18 years old) with T2DM 70 
who underwent bariatric surgery at our centre in the UK between January 2005 and 
December 2012. Data regarding patients who had bariatric surgery and their diabetes status 
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were obtained from a prospectively maintained bariatric surgery database which is kept up 
to date by the weight management team. Renal function (as measured by estimated 
glomerular filtration rate (eGFR))Data regarding eGFR was obtained from the electronic 75 
patients records. Baseline eGFR was defined as the latest eGFR available within 1 month 
preceding surgery. Follow-up eGFR was the latest available on our hospital electronic 
system post-surgery. Patients with no baseline or follow-up eGFR were excluded from 
analysis.  eGFR was calculated using the MDRD (Modification of Diet in Renal Disease) 
formula. eGFR ≥ 120 mlsml/min/1.73m2 was considered to be consistent with hyperfiltration as in 80 
previous studies 23-25. 
Data regarding patients with T2DM who did not undergo bariatric surgery (“routine care”) 
were obtained from another prospective study assessing the pathogenesis of microvascular 
complications in patients with T2DM. The comparator prospective study included adults 
with T2DM and excluded patients with end-stage renal disease. Patients in this group were 85 
recruited from the diabetes clinic at the same centre in which the bariatric surgery was 
performed 2009-2011.  
The comparator “routine care” group data was collected as part of a project that was 
approved by the Warwickshire Research Ethics Committee (REC number 08/H1211/145). 
The data regarding patients who underwent bariatric surgery and their eGFR were collected 90 
during routine clinical care and as part of health service evaluation assessing the outcomes 
of bariatric surgery at our centre, and hence ethical approval was not required.  
Data analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA). Data was 
presented as frequencies or mean (SD) or median (IQR) depending on data distribution. 
Independent continuous variables were compared using the Student’s t-test. Paired t-test 95 
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was used to compare pre- and post- surgical parameters.  Non-parametric tests were used if 
the data was not normally distributed. Pearson or Spearman tests (depending on data 
distribution) were used to correlate changes in eGFR with changes in metabolic parameters. 
Categorical variables were compared using the Chi-squared test. Multiple linear regression 
models were used to assess predictors of study-end eGFR in patients who underwent 100 
bariatric surgery and to assess the relationship between bariatric surgery vs. routine care 
and study-end eGFR. Predictors inserted in the models based on factors that are related to 
the outcome measure. The linear regression models were assessed for multicollinearity, 
homoscedasticity and influential cases and the residuals were assessed for normality. A sub-
group analysis based on the type of the bariatric surgical procedure and baseline eGFR 105 
assessing the impact of bariatric surgery on eGFR in patients with eGFR < 60 
mlsml/min/1.73m2 was also performed. Changes to eGFR were also compared between 
patients with T2DM who received bariatric surgery vs. routine care in a subgroup of 
patients. A p value < 0.05 was considered significant. 
Results 110 
Between January 2005 and December 2012, 565 patients with T2DM underwent bariatric 
surgery at our centre. Out of the 565 patients, only 163 had a baseline and follow-up eGFR 
measurements. There were no difference in age, gender, baseline weight or baseline BMI 
between those who were included and those were excluded from the analysis. 
Of the 163 patients who underwent bariatric surgery, 66.9% (n=109) were women, 60.7% 115 
(n=99) received laparoscopic adjustable gastric banding (LAGB), 28.98% (n=47) Roux-en-Y 
gastric bypass (RYGB), 5.5% (n=9) laparoscopic sleeve gastrectomy (LSG) and 4.9% (n=8) had 
the type of surgery unrecorded in the database. The mean patient age at the time of 
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bariatric surgery was 48.5±8.8 years (range 26-74 years). Patients were followed up for a 
median of 2 years post surgery (range 1.3-9.9 years, mean ± SD 3.04±2.3 years).  120 
Bariatric surgery resulted in significant improvements in HbA1c (60.5±18.7 mmol/mol vs.  
52.6±18.2mmol/mol; p <0.001) and BMI (50.8±9.1 kg/m2 vs. 40.4±9.2 kg/m2; p <0.001) (data 
available on baseline and study-end HbA1c and BMI in 157 and 152 patients respectively). 
Bariatric surgery and CKD 
Bariatric surgery resulted in a significant improvement in eGFR particularly in patients with 125 
baseline eGFR ≤<60 ml/min/1.73m2 (mainly indicating CKD stage 3) (n=15/163, 9.2%) (Table 
1)  
The change in eGFR (defined as study end – baseline values) was greater in patients with 
baseline eGFR ≤< 60 ml/min/1.73m2 vs. those with baseline eGFR ≥ > 60 ml/min/1.73m2 
(14.0 (4.0-20.0) ml/min/1.73m2 vs. 4.0 (-6.8-10.0) ml/min/1.73m2; p=0.009 using the Mann-130 
Whitney U test). 
The change in eGFR was greater in patients who had RYGB compared to LAGB and VSG (9.0 
(1.0-14.0) mls/min/1.73m2 vs. 4.0 (-8.0-9.0) mls/min/1.73m2 vs. 2.0 (-9.5-16.0) 
mls/min/1.73m2 for RYGB, LAGB and VSG respectively; p= 0.027).  There were no 
differences in eGFR change between men and women (p=0.95). 135 
Baseline eGFR (B=0.65, p<0.001), follow-up duration (B=-1.6, p=0.002) and baseline HbA1c 
(B= -0.14, p=0.03) were independent predictors of study-end eGFR after adjustment for age, 
baseline eGFR, baseline HbA1c, baseline BMI, HbA1c change, BMI change, and follow-up 
duration (R2 for the model 0.55). 
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Subgroup analysis based on baseline eGFR and bariatric surgical procedure (Table 2) showed 140 
that LAGB and RYGB improved eGFR in patients with baseline eGFR ≤ 60 ml/min/1.73m2 and 
60 to < 90 ml/min/1.73m2. In patients with eGFR 90 to < 120 ml/min/1.73m2 LAGB resulted 
in improvements in eGFR while RYGB had no impact on eGFR. In patients with 
hyperfiltration (eGFR ≥ 120 ml/min/1.73m2) and received LAGB eGFR improved (Table 2). 
Bariatric surgery vs. routine care: Uni- and multi- variable analysis 145 
Patients in the routine care group were older (p<0.001) and had higher baseline HbA1c 
compared (p<0.001) to the bariatric surgery group; while the surgical group were heavier 
(p<0.001) and had on average slightly longer follow-up (p=0.02) (Table 23). Patients in the 
routine care group had a mean±SD blood pressure of 130.0 ± 17.3/78.2 ± 10.4 mmHg. The 
routine care group were intensively treated with glucose and blood pressure lowering 150 
agents including: insulin in 53.3% (n=120), oral glucose lowering agents 92.4% (n=208), 
renin-angiotensin-aldosterone system inhibitors 69.8% (n=157) and 80% (n=180) received 
one or more antihypertensive. The median number of antihypertensives used per patient in 
the routine care was 2 (IQR 1-2). 
The baseline eGFR was similar between groups but the study-end eGFR and the eGFR 155 
change were greater in the bariatric surgery group compared to the routine care group 
(Table 34). In the bariatric surgery group eGFR increased while in the routine care group 
eGFR decreased during the follow-up (p<0.001) (Table 4). This difference was particularly 
evident in patients with baseline eGFR ≤ 60 ml/min/1.73m2 (p<0.001) (Table 4). 
After adjustment for baseline differences, bariatric surgery was independently and 160 
significantly (p<0.001) associated with higher study-end eGFR (Table 5). Other independent 
predictors of study-end eGFR included baseline eGFR, age and follow-up duration (Table 5). 
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Discussion 
This study shows that bariatric surgery resulted in significant improvements in renal 
functioneGFR in morbidly obese patients with T2DM particularly in those with an eGFR ≤<60 165 
mlsml/min/1.73m2. Furthermore, while bariatric surgery improved renal functioneGFR, the 
renal functioneGFR continued to decline gradually in a comparative group of patients with 
T2DM who did not have bariatric surgery. Post-surgery eGFR was not related to post surgical 
changes in BMI or HbA1c but was related to baseline eGFR, baseline HbA1c and age. The 
favourable impact of bariatric surgery on renal functioneGFR compared to routine care was 170 
independent of the between-group differences and occurred despite the slightly longer 
follow-up duration in the surgical group. 
Despite improvements in the management of cardiovascular disease risk factors and 
glycaemic measures in patients with diabetes, ESRD remains very common and the decline 
in ESRD was far less than that observed in relation to cardiovascular disease and other 175 
diabetes-related complications in the US over 2 decades 5. This in part could be due to the 
lack of effective weight loss strategies in patients with T2DM as most of the glucose 
lowering agents are either weight neutral or cause weight gain except GLP-1 receptor 
agonists and SGLT-2 inhibitors which were introduced more recently in 2005 and 2013 
respectively 26;27.  180 
Obesity, which is very common in patients with T2DM, is known to be a risk factor for ESRD 
via multifactorial mechanisms with weight loss having been shown to have a favourable 
impact on CKD and proteinuria 6-12.  A recent systematic review showed that weight loss 
following lifestyle changes, pharmacotherapy or bariatric surgery was generally associated 
with either improvements or stability in renal function and markers of CKD (such as 185 
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albuminuria or proteinuria) 28. There are however conflicting results and the data regarding 
bariatric surgery was from uncontrolled and non-randomised studies of duration of 1 year 
or less 28;29. More recent studies have shown that eGFR was reduced in patients with 
hyperfiltration and improved in patients with impaired renal function post RYGB and LSG 29-
31. 190 
Studies regarding the impact of bariatric surgery on eGFR in patients with diabetes are 
limited and there are no randomised controlled trials reported 8;29;32. In a study of 50 
patients with newly diagnosed T2DM, biliary pancreatic diversion was associated with 
improvements in eGFR compared to a decline in eGFR in the comparator arm over 10 years 
33. Another study of 30 patients with T2DM who had either LAGB, LSG or RYGB showed that 195 
surgery resulted in reductions in cCystatin C levels suggesting improvements in renal 
function 34. In another study that included a subgroup of patients with T2DM, RYGB resulted 
in improvements in glomerular hyperfiltration 12 months post surgery 35. 
The impact of bariatric surgery on renal functioneGFR could be difficult to elucidate as on 
one hand bariatric surgery results in sustained and significant improvements in many CKD 200 
risk factors (such as weight, glycaemia, BP, inflammation etc.) 14-18; while on the other hand 
the effects of the metabolic memory resulting in sustained vascular dysfunction despite 
improvements in glycaemic control might blunt the potential beneficial effects of bariatric 
surgery on renal functionthe kidneys 21. This was supported by a recent study showing that 
while bariatric surgery might have a favourable impact on diabetic retinopathy in patients 205 
with T2DM, sight threatening retinopathy might develop for the first time after bariatric 
surgery 36. The findings of our current study show similar results in that although bariatric 
surgery had a beneficial effect on renal functioneGFR in patients with T2DM; baseline HbA1c 
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remained an independent predictor of the study-end eGFR regardless of the improvements 
in HbA1c that occurred post surgery. 210 
One of the main factors regarding the difficulty in assessing the impact of bariatric surgery 
on renal function is the methods used to assess renal functioncalculated eGFR. Creatinine-
based eGFR is widely used in routine care as it is readily available and can be used in large 
epidemiological studies; however, there have been concerns that eGFR could be misleading 
in patients post bariatric surgery due to the loss of muscle mass resulting in a reduction in 215 
the supply of creatinine. In fact, creatinine-based eGFR is not validated in obese individuals 
and as obese individuals have higher muscle mass creatinine-based eGFR may 
underestimate renal function is such population 37. Recent studies demonstrated that 
cCystatin-C based eGFR was more closely related to the measured GFR than creatinine 
based eGFR post bariatric surgery, which is not surprising considering that cystatin-C may 220 
not be as closely related to muscle mass as creatinine and is not affected by dietary intake; 
37. Indeed studies using measured rather than estimated GFR showed that bariatric surgery 
results in renal function decline and aA recent study in which measured and estimated GFR 
were performed in the same population 6 and 12 months following bariatric surgery showed 
a drop in measured GFR which was not detected by eGFR 38. However, despite the 225 
limitations of using creatinine-based eGFR a recent study showed that calculating eGFR 
based on creatinine and cystatin-C combined using the CKD-EPI was superior to calculating 
eGFR  based on either creatinine or cysctatin-C alone when compared to measured GFR; but 
in this study the surgery type was not defined and almost all included patients had normal 
renal function at baseline37. 230 
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In our study we have used estimated and not measured GFR and in the absence of a 
measured muscle mass before and after surgery in this study we cannot completely rule out 
the impact of reduction in creatinine generation on our results. However, there are several 
factors to suggest that loss of muscle mass do not explain our findings. The loss of muscle 
mass following bariatric surgery is mainly reported following biliary pancreatic diversion, 235 
RYGB and LSG while several studies showed little to no loss of muscle mass following 
LAGB39-41, which constitute the majority of the patients in this study. In addition, in this 
study the impact of LAGB on eGFR was similar to the impact of RYGB, particularly in patients 
with eGFR < 90 ml/min/1.73m2 (Table 2), despite the predicted differences in muscle mass 
loss following LAGB and RYGB. A recent study showed that changes in muscle mass at three 240 
months were predicted by fat mass loss and changes in glycaemia, whereas change in 
glycaemia was the only 12-month determinant associated with muscle mass changes 
following RYGB or LSG 42. Our results show that the changes in eGFR were independent of 
changes in BMI and changes in HbA1c suggesting that the impact of bariatric surgery in our 
study may not totally reflect the changes in muscle mass. Furthermore, the time course of 245 
muscle mass loss suggest that muscle mass loss recovers, at least partially, at 12 months 
compared to 3 months post-surgery 42; considering that the average follow-up duration in 
this study is 3.04 years and the range is 1.3-9.9 years, this would suggest that the impact of 
muscle mass loss might have been lessened further with the longer follow-up. Finally, with 
loss of creatinine supplies due to muscle mass loss after surgery it would be expected that 250 
eGFR would increase regardless of baseline eGFR, but the results in Table 2 show that eGFR 
has indeed dropped in patients who received LAGB with baseline eGFR ≥ 90 ml/min/1.73m2 
and that RYGB and LSG did not result in eGFR changes in patients with baseline eGFR 
between 90 and < 120 ml/min/1.73m2. All the above factors suggest that loss of creatinine 
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generation, caused by muscle mass loss post bariatric surgery, does not fully explain the 255 
findings of this study. 
The mechanisms underpinning the observed impact of bariatric surgery on renal 
functioneGFR are unclear. Changes in BMI and HbA1c did not predict renal functioneGFR 
changes in this study but improvements in other unmeasured CKD risk factors such as 
inflammation, sympathetic tone, the RAAS, OSA and endothelial function might explain the 260 
favourable impact of bariatric surgery on eGFR compared to routine care. The higher 
improvements in eGFR in the RYGB group compared to the LSG and LAGB groups suggest 
that neuro-hormonal mechanisms might play a role in the impact of bariatric surgery on 
eGFR.  
Our study does however have several strengths. Our study has a longer follow up and larger 265 
sample size than previous studies that assessed the relationship between CKD and bariatric 
surgery in patients with T2DM (except the study that used biliary pancreatic diversion) 8;29;32-
35. In addition we have compared the changes in renal functioneGFR in patients who 
received bariatric surgery with patients receiving their medical treatmentroutine care for 
T2DM in the same center and hence received the same standards of care. LAGB was the 270 
predominant surgical procedure in this study and most of the literature examining the 
impact of bariatric surgery on renal function in T2DM has so far focused on RYGB or 
LSG8;29;32-35. On the other hand, our study has several limitations.  Our data did not include 
BP which has an important impact on renal function22. However, the routine care cohort in 
this study had very good BP control (mean 130/78 mmHg) which should have minimised this 275 
effect. The observational nature of the study means that some confounders may not have 
been accounted for at baseline. There were also several differences in the routine care 
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group compared to the bariatric surgery group; however despite adjustment for these 
differences bariatric surgery remained an independent predictor of a higher study-end eGFR 
compared to routine care. Another limitation is the number of patients who were not 280 
included in the analysis due to missing data; although we could not detect any significant 
differences between patients who were included and those who were excluded from the 
analysis, we cannot rule out differences in other variables that were not measured or were 
not available on our electronic records. 
In conclusion, bariatric surgery is associated with improvements in renal functioneGFR in 285 
patients with T2DM, particularly in those with impaired pre-operative renal function. 
Compared to routine care, bariatric surgery was associated with better study-end renal 
functioneGFR. Future studies using more assessments of renal function that are not 
dependent on muscle mass (such as cCystatin-C based eGFR or using other methods such as 
free light chains), and longer follow up are needed to assess whether bariatric surgery can 290 
prevent or delay the development of ESRD in patients with T2DM. Studies including a larger 
proportion of patients with T2DM and impaired renal function are also needed to clarify 
whether bariatric surgery can improve renal function in this population. Whether the impact 
of bariatric surgery varies between different surgical approaches also requires additional 
investigation. 295 
 
 
 
 
14 
 
Reference List 300 
 
 (1)  Leiter LA. The prevention of diabetic microvascular complications of diabetes: Is there a role 
for lipid lowering? Diabetes Research and Clinical Practice 2005; 68(Supplement 2):S3-S14. 
 (2)  Bakris GL. Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in 
Patients With Type 2 Diabetes Mellitus. Mayo Clinic Proceedings 2011; 86(5):444-456. 305 
 (3)  Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract End 
Met 2008; 4(8):444-452. 
 (4)  Afghahi H, Cederholm J, Eliasson B et al. Risk factors for the development of albuminuria and 
renal impairment in type 2 diabetesthe Swedish National Diabetes Register (NDR). 
Nephrology Dialysis Transplantation 2011; 26(4):1236-1243. 310 
 (5)  Gregg EW, Li Y, Wang J et al. Changes in Diabetes-Related Complications in the United 
States, 19902010. N Engl J Med 2014; 370(16):1514-1523. 
 (6)  MacLaughlin HL, Hall WL, Sanders TA, Macdougall IC. Risk for chronic kidney disease 
increases with obesity: Health Survey for England 2010. Public health nutrition 2015;1-6. 
 (7)  Hsu Cy, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body Mass Index and Risk for End-315 
Stage Renal Disease. Annals of Internal Medicine 2006; 144(1):21-28. 
 (8)  Rao B, Bhattacharya A, Agrawal V. Renal outcomes of bariatric surgery in obese adults with 
diabetic kidney disease. J Nephrol 2014; 27(4):361-370. 
 (9)  Wickman C, Kramer H. Obesity and Kidney Disease: Potential Mechanisms. Seminars in 
Nephrology 33(1):14-22. 320 
 (10)  Tahrani AA, Ali A, Raymond NT et al. Obstructive Sleep Apnea and Diabetic Nephropathy: A 
cohort study. Diabetes Care 2013; 36(11):3718-3725. 
 (11)  Tahrani AA, Dubb K, Raymond NT et al. Cardiac autonomic neuropathy predicts renal 
function decline in patients with type 2 diabetes: a cohort study. Diabetologia 2014; 
57(6):1249-1256. 325 
 (12)  Afshinnia F, Wilt TJ, Duval S, Esmaeili A, Ibrahim HN. Weight loss and proteinuria: systematic 
review of clinical trials and comparative cohorts. Nephrology Dialysis Transplantation 2010; 
25(4):1173-1183. 
 (13)  Sjöström L, Peltonen M, Jacobson P. Bariatric surgery and long-term cardiovascular events. 
JAMA 2012; 307(1):56-65. 330 
 (14)  Dixon JB, O'Brien PE, Playfair J. Adjustable gastric banding and conventional therapy for type 
2 diabetes: A randomized controlled trial. JAMA 2008; 299(3):316-323. 
 (15)  Ikramuddin S, Korner J, Lee W. Roux-en-y gastric bypass vs intensive medical management 
for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery 
study randomized clinical trial. JAMA 2013; 309(21):2240-2249. 335 
15 
 
 (16)  Schauer PR, Kashyap SR, Wolski K et al. Bariatric Surgery versus Intensive Medical Therapy in 
Obese Patients with Diabetes. N Engl J Med 2012; 366(17):1567-1576. 
 (17)  Schauer PR, Bhatt DL, Kirwan JP et al. Bariatric Surgery versus Intensive Medical Therapy for 
Diabetes 3-Year Outcomes. N Engl J Med 2014; 370(21):2002-2013. 
 (18)  Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, Diabetes, and Cardiovascular Risk 340 
Factors 10 Years after Bariatric Surgery. N Engl J Med 2004; 351(26):2683-2693. 
 (19)  Mas-Lorenzo A, Benaiges D, Flores-Le-Roux JA et al. Impact of Different Criteria on Type 2 
Diabetes Remission Rate After Bariatric Surgery. OBES SURG 2014; 24(11):1881-1887. 
 (20)  Sjöström L, Peltonen M, Jacobson P. Association of bariatric surgery with long-term 
remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 345 
2014; 311(22):2297-2304. 
 (21)  Reddy M, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and 
metabolic memory. Diabetologia 2014;1-13. 
 (22)  Jackson S, le Roux C, Docherty N. Bariatric Surgery and Microvascular Complications of Type 
2 Diabetes Mellitus. Curr Atheroscler Rep 2014; 16(11):1-9. 350 
 (23)  Bjornstad P, Cherney DZ, Snell-Bergeon JK et al. Rapid GFR decline is associated with renal 
hyperfiltration and impaired GFR in adults with Type 1 diabetes. Nephrology Dialysis 
Transplantation 2015; 30(10):1706-1711. 
 (24)  Hasslacher C, Kulozik F. Influence of renal function on serum concentration of 1,5-
anhydroglucitol in type 2 diabetic patients in CKD stages I-III: A comparative study with 355 
HbA1c and glycated albumin. J Diabetes 2015;n/a. 
 (25)  Oh SW, Han KH, Han SY. Associations between Renal Hyperfiltration and Serum Alkaline 
Phosphatase. PLoS ONE 2015; 10(4):e0122921. 
 (26)  Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and 
future developments in treatment. The Lancet 2011; 378(9786):182-197. 360 
 (27)  Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. The Lancet 
Diabetes & Endocrinology 2013; 1(2):140-151. 
 (28)  Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: a 
systematic review. Nephrology Dialysis Transplantation 2013; 28(suppl 4):iv82-iv98. 
 (29)  Neff KJ, Frankel AH, Tam FW, Sadlier DM, Godson C, le Roux CW. The effect of bariatric 365 
surgery on renal function and disease: a focus on outcomes and inflammation. Nephrology 
Dialysis Transplantation 2013; 28(suppl 4):iv73-iv82. 
 (30)  Hou CC, Shyu RS, Lee WJ, Ser KH, Lee YC, Chen SC. Improved renal function 12 months after 
bariatric surgery. Surgery for Obesity and Related Diseases 2013; 9(2):202-206. 
 (31)  Reid TJ, Saeed S, McCoy S, Osewa AA, Persaud A, Ahmed L. The effect of bariatric surgery on 370 
renal function. Surgery for Obesity and Related Diseases 2014; 10(5):808-813. 
16 
 
 (32)  Jackson S, le Roux C, Docherty N. Bariatric Surgery and Microvascular Complications of Type 
2 Diabetes Mellitus. Curr Atheroscler Rep 2014; 16(11):1-9. 
 (33)  Iaconelli A, Panunzi S, De Gaetano A et al. Effects of Bilio-Pancreatic Diversion on Diabetic 
Complications: A 10-year follow-up. Diabetes Care 2011; 34(3):561-567. 375 
 (34)  Fenske WK, Dubb S, Bueter M et al. Effect of bariatric surgery-induced weight loss on renal 
and systemic inflammation and blood pressure: a 12-month prospective study. Surgery for 
Obesity and Related Diseases 2013; 9(4):559-568. 
 (35)  Saliba J, Kasim NR, Tamboli RA et al. Roux-en-Y gastric bypass reverses renal glomerular but 
not tubular abnormalities in excessively obese diabetics. Surgery 2010; 147(2):282-287. 380 
 (36)  Amin AM, Wharton HM, Clarke M, Syed A, Dodson PM, Tahrani AA. The impact of bariatric 
surgery on retinopathy in patients with type 2 diabetes: a retrospective cohort study. 
Surgery for Obesity and Related Diseases. 
 (37)  Friedman AN, Moe S, Fadel WF et al. PREDICTING THE GLOMERULAR FILTRATION RATE IN 
BARIATRIC SURGERY PATIENTS. Am J Nephrol 2014; 39(1):8-15. 385 
 (38)  Lieske JC, Collazo-Clavell ML, Sarr MG, Rule AD, Bergstralh EJ, Kumar R. Gastric Bypass 
surgery and measured and estimated GFR in women. Am J Kidney Dis 2014; 64(4):663-665. 
 (39)  Coupaye M, Bouillot JL, Poitou C, Schutz Y, Basdevant A, Oppert JM. Is Lean Body Mass 
Decreased after Obesity Treatment by Adjustable Gastric Banding? OBES SURG 2007; 
17(4):427-433. 390 
 (40)  Guida B, Belfiore A, Angrisani L et al. Laparoscopic gastric banding and body composition in 
morbid obesity. Nutrition, Metabolism and Cardiovascular Diseases 15(3):198-203. 
 (41)  Chaston TB, Dixon JB, O'Brien PE. Changes in fat-free mass during significant weight loss: a 
systematic review. Int J Obes 2006; 31(5):743-750. 
 (42)  Vaurs C, Diméglio C, Charras L, Anduze Y, Chalret du Rieu M, Ritz P. Determinants of changes 395 
in muscle mass after bariatric surgery. Diabetes & Metabolism 2015. 
 
 
 
 400 
 
 
 
 
 405 
17 
 
Table 1: The impact of bariatric surgery on renal function in patients with T2DM. Change in eGFR was 
calculated as study-end – baseline values. Data presented as median (IQR) and mean±SD. P values 
were calculated using the related samples Wilcoxon Signed Rank test as the follow-up eGFR data was 
not normally distributed. 
  Baseline Follow-up P value 
eGFR 
(mlsml/min/1.73m2) 
Total population 86.0 (73.0-100.0) 
86.5 ± 20.8 
92.0 (77.0-101.0) 
88.8 ± 18.9 
0.003 
In eGFR ≤< 60 48.0 (42.0-57.0) 
47.7 ± 9.1 
61.0 (55.0-63.0) 
60.7 ± 14.0 
0.004 
 410 
Table 2: The impact of bariatric surgery on eGFR based on surgical procedure and baseline eGFR 
category. Data presented as mean ± SD. NA: Not applicable; LAGB: laparoscopic adjustable gastric 
banding; RYGB: Roux-en-Y gastric bypass; LSG: laparoscopic sleeve gastrectomy. This analysis 
excluded the 8 patients that had the type of surgery missing from the database. P values were 
calculated using the related samples Wilcoxon Signed Rank test 415 
Baseline eGFR 
ml/min/1.73m2 
Surgical 
procedure 
Baseline eGFR 
ml/min/1.73m2 
Study-end eGFR 
ml/min/1.73m2 
P value 
≤ 60 LAGB (n=11) 48.4 ± 9.4 56.4 ± 9.7 0.036 
LSG (n=0) NA NA NA 
RYGB (n=4) 46.5 ± 9.5 72.5 ± 18.7 0.068 
>60 to < 90 LAGB (n=44) 76.7 ± 8.1 84.1 ± 13.7 < 0.001 
LSG (n=5) 75.2 ± 8.8 79.6 ± 19.7 0.69 
RYGB (n=25) 78.0 ± 6.9 85.4 ± 14.5 0.003 
90 to < 120 LAGB (n=36) 102.7 ± 7.3 95.8 ± 13.8 0.019 
LSG (n=4) 103.8 ± 9.1 100.3 ± 15.0 0.47 
RYGB (n=17) 99.5 ± 9.7 100.8 ± 14.1 0.19 
≥ 120 
(hyperfiltration) 
LAGB (n=8) 128.3 ± 7.8 111.4 ± 19.3 0.036 
LSG (n=0) NA NA NA 
RYGB (n=1) 128.0 150.0 NA 
 
 
 
 
 420 
 
 
 
Table 32: Summary of patients’ baseline characteristics in the bariatric surgery group vs. routine care 
group. Data presented as mean±SD.*P value calculated using Mann Whitney U test as the data was 425 
not normally distributed 
18 
 
 Bariatric surgery 
(n=163) 
Routine care 
(n=225) 
P value 
Age (years) 48.5±8.8 57.1±12.1 < 0.001 
Women 66.9% (n=109) 42.7% (n=96) < 0.001 
HbA1c (mmol/mol) 59.6±19.6 66.1±16.0 < 0.001 
BMI (Kg/m2) 50.8±9.1 33.7±8.3 < 0.001 
Follow-up (years) 3.0±2.3 2.5±0.7 0.02* 
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Table 43: Comparison of the eGFR and eGFR change between patients who had bariatric 450 
surgery vs. routine care in the total study population and in those with baseline eGFR ≤ 60 
ml/min/1.73m2. Data presented as mean±SD *P value calculated using Mann Whitney U test 
as the data was skewed Table 4: Comparison of the eGFR and eGFR change between patients who 
19 
 
have baseline eGFR ≤ 60  mls/min/1.73m2 and had bariatric surgery vs. routine care. *P value 
calculated using Mann Whitney U test as the data was skewed 455 
 
Total study population Bariatric surgery 
(n=163) 
Routine care 
(n=225) 
P value 
Baseline eGFR 
ml/min/1.73m2 
86.5±20.8 86.1±26.5 0.89 
Study-end eGFR 
ml/min/1.73m2 
88.8±18.9 81.0±27.5 0.001 
eGFR change (study 
end minus baseline 
values) 
ml/min/1.73m2 
2.3±15.3 -5.1±11.0 <0.001* 
Patients with baseline 
eGFR ≤ 60 
ml/min/1.73m2 
Bariatric surgery 
(n=15) 
Routine care 
(n=41) 
P value 
Baseline eGFR 
ml/min/1.73m2 
47.9±9.1 46.9±11.2 0.72 
Study-end eGFR 
ml/min/1.73m2 
60.7±14.0 41.5±14.3 < 0.001 
eGFR change (study 
end minus baseline 
values) 
ml/min/1.73m2 
12.8±13.2 -5.2±10.3 < 0.001* 
 
 
 
 460 
 
Table 5: Summary of multiple linear regression assessing the impact of bariatric surgery on study-
end eGFR. Outcome measure: study-end eGFR. R2 for the model= 0.76 
 
Variable B P 
Baseline eGFR 0.822 < 0.001 
20 
 
Baseline BMI -0.067 0.36 
Baseline HbA1c -0.385 0.33 
Gender 0.603 0.65 
Baseline age -0.211 0.002 
Follow-up duration -1.813 < 0.001 
Bariatric surgery vs. routine 
care 
7.787 < 0.001 
 465 
